| Literature DB >> 35326852 |
Guilherme Paz Monteiro1, Roberta Torres de Melo1, Micaela Guidotti-Takeuchi1, Carolyne Ferreira Dumont1, Rosanne Aparecida Capanema Ribeiro1, Wendell Guerra2, Luana Munique Sousa Ramos2, Drielly Aparecida Paixão2, Fernanda Aparecida Longato Dos Santos1, Dália Dos Prazeres Rodrigues3, Peter Boleij4, Patrícia Giovana Hoepers5, Daise Aparecida Rossi1.
Abstract
Salmonella spp. continues to figure prominently in world epidemiological registries as one of the leading causes of bacterial foodborne disease. We characterised 43 Brazilian lineages of Salmonella Typhimurium (ST) strains, characterized drug resistance patterns, tested copper (II) complex as control options, and proposed effective antimicrobial measures. The minimum inhibitory concentration was evaluated for seven antimicrobials, isolated and combined with the copper (II) complex [Cu(4-FH)(phen)(ClO4)2] (4-FH = 4-fluorophenoxyacetic acid hydrazide and phen = 1,10-phenanthroline), known as DRI-12, in planktonic and sessile ST. In parallel, 42 resistance genes were screened (PCR/microarray). All strains were multidrug resistant (MDR). Resistance to carbapenems and polymyxins (86 and 88%, respectively) have drawn attention to the emergence of the problem in Brazil, and resistance is observed also to CIP and CFT (42 and 67%, respectively), the drugs of choice in treatment. Resistance to beta-lactams was associated with the genes blaTEM/blaCTX-M in 39% of the strains. Lower concentrations of DRI-12 (62.7 mg/L, or 100 μM) controlled planktonic and sessile ST in relation to AMP/SUL/TET and AMP/SUL/TET/COL, respectively. The synergistic effect provided by DRI-12 was significant for COL/CFT and COL/AMP in planktonic and sessile ST, respectively, and represents promising alternatives for the control of MDR ST.Entities:
Keywords: food safety; multi drug resistance (MDR); salmonellosis
Year: 2022 PMID: 35326852 PMCID: PMC8944508 DOI: 10.3390/antibiotics11030388
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
The distribution of MIC (mg/L) and percentages of resistance in ST isolated from food and human samples in Brazil between 2011 and 2017.
| Concentrations | AMP | TET | MER | COL | CFT | CIP | SUL | DRI-12 |
|---|---|---|---|---|---|---|---|---|
| A | - | 24 | 5 | 4 | 1 | 16 | - | - |
| B | - | - | - | - | - | - | - | - |
| C | - | 1 | - | 1 | 1 | 4 | - | - |
| D | - | - | 1 | - | 4 | 4 | - | - |
| E | 1 | - | 2 | 3 | 8 | 1 | - | - |
| F | 14 | 1 | 18 | 22 | 19 | 11 | - | 1 |
| G | 6 | 2 | 17 | 10 | 8 | 4 | - | 2 |
| H | 1 | 1 | - | - | - | 2 | - | 17 |
| I | 2 | 12 | - | - | - | - | 1 | 21 |
| J | 19 | 2 | - | 3 | 2 | 1 | 42 | 2 |
|
| 22 (51.2) | 17 (39.5) | 35 (81.4) | 35 (81.4) | 10 (23.3) | 1 (2.3) | 43 (100) | - |
|
| 28 (65.1) | 18 (41.8) | 37 (86) | 38 (88.4) | 29 (67.4) | 18 (41.8) | 43 (100) | - |
|
| 15 (34.8) | 25 (58.1) | 6 (13.9) | 5 (11.6) | 14 (32.5) | 25 (58.1) | 0 (0) | - |
|
| 32 mg/L | <0.5 mg/L | 4 mg/L | 4 mg/L | 2 mg/L | 0.0312 mg/L | >2048 mg/L | 62.68 mg/L |
|
| >64 mg/L | 64 mg/L | 8 mg/L | 8 mg/L | 4 mg/L | 0.25 mg/L | >2048 mg/L | 62.68 mg/L |
A–J: doubling and increasing variations in concentrations for each antimicrobial. AMP: ampicillin (A: <0.5 mg/L, J: >64 mg/L); TET: tetracycline (A: <0.5 mg/L, J: >64 mg/L); MER: meropenem (A: <0.25 mg/L, J: >32 mg/L); COL: colistin (A: <0.25 mg/L, J: >32 mg/L); CFT: ceftriaxone (A: <0.125 mg/L, J: >16 mg/L); CIP: ciprofloxacin (A: <0.0078 mg/L, J: >1 mg/L); SUL: sulfisoxazole (A: <16 mg/L, J: >2048 mg/L); and DRI-12—copper complex [Cu(4-FH)(phen)(ClO4)2] (A: <0.49 mg/L, J: >62.68 mg/L). __ (line)—cut-off point according to CLSI 2021 [24]; dark grey highlight—resistance (R); light grey—intermediate resistance (I); white—susceptible (S); and (%)—resistance percentage.
Figure 1The effect of antimicrobial treatment, with and without addition of the copper complex, on the free and biofilm forms of five ST strains. The results represent means with the standard deviation (error bars) of three independent repetitions with three replicates. +DRI-12: supplementation with [Cu(4-FH)(phen)(ClO4)2] at concentrations of 10 and 45 μM, respectively, for planktonic (PL) and biofilm (BF) forms of ST. ATM concentration: antimicrobial concentration. 1–14: doubling and increasing variations in concentrations for each antimicrobial. AMP: ampicillin (1: <0.5 μg/mL, 14: >1024 μg/mL); TET: tetracycline (1: <0.5 μg/mL, 14: >1024 μg/mL); MER: meropenem (1: <0.25 μg/mL, 14: >512 μg/mL); COL: colistin (1: <0.25 μg/mL, 14: >512 μg/mL); CFT: ceftriaxone (1: <0.125 μg/mL, 14: >256 μg/mL); CIP: ciprofloxacin (1: <0.0078 μg/mL, 14: >16 μg/mL); and SUL: sulfisoxazole (1: <16 μg/mL, 12: >8192 μg/mL). Red line: cutoff point according to CLSI (2021). ns: no statistical difference in the analysis between strains for each treatment. * p < 0.05; using Mann–Whitney test.
Figure 2SEM images of biofilms with and without 100 μM of the copper complex treatment in two strains of ST. (A,B) control group with normal biofilm structure; (C) group treated with DRI-12, demonstrating the presence of a thick layer of extracellular matrix, and razing of the matrix structure and bacterial exposure; and (D) treatment with DRI-12, with biomass fragmentation.
Genes and functions, amplification conditions, amplicon size and references used in ST assessment.
| Gene | Amplicon (pb) | Function | Amplification | Reference | |
|---|---|---|---|---|---|
|
| CAGCGGTAAGATCCTTGAGA | 643 | β-lactam resistance | 30× (94 °C, 45 s/50 °C, 45 s/72 °C, 90 s) | [ |
|
| GGCCGCGTAGGCATGATAGA | 714 | β-lactam resistance | 30× (94 °C, 45 s/56 °C, 45 s/72 °C, 90 s) | [ |
|
| TGGGTRAARTARGTSACCAGAAYCAGCGG | 593 | β-lactam resistance | 30× (94 °C, 45 s/58 °C, 60 s/72 °C, 90 s) | [ |
|
| TGGCCGTTGCCGTTATCTAC | 870 | β-lactam resistance | 30× (94 °C, 45 s/59 °C, 53 s/72 °C, 90 s) | [ |
|
| AGAGGATTTCTCACGCCAGG | 580 | Fluoroquinolone resistance | 35× (95 °C, 60 s/54 °C, 60 s/72 °C, 90 s) | [ |
|
| GCAAGTTCATTGAACAGGGT | 428 | Fluoroquinolone resistance | 35× (95 °C, 60 s/54 °C, 60 s/72 °C, 90 s) | [ |
Genes identified by CT103-XL associated with bacterial resistance by producing different enzymes responsible for resistance to antimicrobials.
| Carbapenamases | Β-Lactamases | AmpCs | MCR | |
|---|---|---|---|---|
| GES | Group CTX-M-1 | TEM 164C | ACC | MCR-1 |
| GIM | Subgroup CTX-M-1 | TEM 164H | ACT/MIR | MCR-2 |
| IMP | Group CTX-M-2 | TEM 164S | CMY I/MOX | |
| KPC | Subgroup CTX-M-3 | TEM 238S | CMY II | |
| NDM | Group CTX-M-8 | SHVwt | DHA | |
| OXA-23 | Group CTX-M-9 | SHV 238A | FOX | |
| OXA-24 | Subgroup CTX-M-15 | SHV 238S | ||
| OXA-48 | Group CTX-M-25 | SHV240K | ||
| OXA-58 | Group CTX-M-32 | BEL | ||
| VIM | TEM wt | GES | ||
| SPM | TEM 404K | PER | ||
| VEB | ||||
Figure 3The chemical structure of [Cu(4-fh)(phen)(ClO4)2].